United States Patent 7,576,221: Claim Scope, Validity Friction, and Competitive Patent Landscape

What does US 7,576,221 actually claim?

US 7,576,221 claims a very broad class of “compounds represented by the formula” with extensive variable substituent definitions, followed by a long list of narrow dependent claim fallbacks (specific substituent selections) and formulation/composition claims. The operative scope is claim 1; all later claims either (a) narrow a subset of substituent variables or (b) add non-structural limitations (composition and combination therapy).

Claim 1 core structure and variable map

Claim 1 is a Markush-style genus defined by:

X¹ = —C(O)— (a carbonyl present in the scaffold)
A² is an aromatic/heteroaromatic/cycloalkyl group (optionally substituted with 1 to 4 substituents from a broad set including alkyl, alkoxy, amino, halo, hydroxy, nitro)
A is a second substitution/side-chain variable that can be:
- H, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, carboxyl, carboxyl ester, aminoacyl, optionally substituted heteroaryl, optionally substituted heterocyclic, optionally substituted cycloalkyl
- with additional constraints on “optionally substituted groups,” including restrictions on oxo (not when A is optionally substituted aryl/heteroaryl) and inclusion of —S(O)R⁹ where R⁹ is defined broadly
R⁸ is one of: alkyl, alkenyl, alkynyl, —CF₃, alkoxy, cyano, halo, hydroxy
R⁴ is -[alkylene]ᵖ₋NR¹⁰R¹¹ where p = 0 to 1
- alkylene is straight chained optionally substituted with selected functional groups
- R¹⁰/R¹¹ are broadly defined (including heterocycles and sulfoxide/sulfone alkyl variants)
- with a conditional constraint: “when R¹⁰ is hydrogen, R¹¹ is hydroxy, alkoxy or substituted alkoxy”
R¹⁵ is one of ethyl, isopropyl, t-butyl, phenyl
R¹⁶ = H or methyl
R¹⁷ = H or methyl
m¹ = 0, 1, or 2
and pharmaceutically acceptable salts/esters/prodrugs

Dependent claims that materially tighten scope

The dependent claims do not merely add minor refinements; several carve out specific substituent selections that can be used as enforcement anchors.

Claim	What it narrows	Substituent values called out
2	R¹⁵	t-butyl
3	R¹⁷	H
4	A (unsubstituted, specific set)	enumerates dozens of heterocycles/aryl groups
5	A (substituted aryl/heteroaryl set)	enumerates specific substituted rings (e.g., 4-t-butylphenyl, 2-chlorophenyl, multiple fluorinated/chlorinated/cyano rings)
6	A (substituted heterocyclic/cycloalkyl set)	aminoacylcyclohexyl variants, quinuclidinyl, oxoprolidinyl variants, etc.
7	A (substituted alkyl set)	numerous functionalized alkyl amines and heteroatom-bearing methyl/alkyl groups
8	A	N-methylaminocarbonyl
9	R⁴ options	detailed enumeration of many specific “—(CH₂)ₙ—NH—…” substituents including amino- and substituted aryl-linked amines
10	A² options	enumerates specific aryl/heteroaryl substituents (phenyl, multiple difluorophenyl, specific thiazole/furan variants, etc.)
11	R¹⁶	H
12	a further depicted substituent (given as ##STR00547##)	enumerates specific phenyl-like substituted aryls including bromine, cyanophenyl, difluorophenyls, trifluoromethylphenyls, etc.
13	Explicit compound list	provides a large set of individually named stereochemical and regiochemical embodiments (benzamide-linked, imidazole-linked structures, etc.)
14	Pharmaceutical composition	compound of claim 1 + pharmaceutically acceptable carrier
15-16	Combination therapy	claim 15 adds “at least one additional agent for treatment of cancer”; claim 16 enumerates a large set of common chemotherapies and biologics

Practical claim breadth: why it matters

For enforcement and freedom-to-operate (FTO), claim 1 is a genus with enormous internal combinatorics:

A² can vary across broad aromatic and heteroaromatic spaces.
A can vary across essentially “many drug-like groups,” including ring systems and functionalized alkyls.
R⁴ is a major diversification handle because it determines the alkylene-NR¹⁰R¹¹ tail architecture and allows many different terminal and internal functional groups.
R⁸, R¹⁵, m¹, R¹⁶, R¹⁷ add further degrees of freedom.

The consequence: claim 1 likely covers many embodiments beyond the specifically listed claim 13 examples, while dependent claims 2-12 and 18 provide more direct “label-like” anchors for litigation by narrowing to particular substituent classes.

Does claim 1 have clear novelty or obviousness pressure?

This is a patent-family and prior-art-positioning question, but the claims themselves provide strong signals about how validity arguments would be structured: the variables are broadly framed, and multiple dependent claims enumerate specific substituent sets that read like typical medicinal chemistry optimization around an existing scaffold.

Where novelty is most vulnerable

Markush breadth across A/A²/R⁴
Claim 1’s broad generic definitions make it harder to argue strict novelty if the prior art shows the same scaffold with similar substituent ranges. A broad genus often faces validity risk if the art discloses a “center of gravity” set of embodiments and the claimed genus covers obvious close variants.
Combination therapy language (claims 15-16)
Adding standard cancer drugs in a formulation/composition claim is often treated as obvious absent a specific synergistic mechanism tied to the claimed compounds. Here, claim 16 lists a wide menu of established agents including irinotecan, topotecan, gemcitabine, imatinib, trastuzumab, platinum drugs, taxanes, and others.
Dependence on “known functional groups”
The substitutions in the Markush definitions rely on standard functional groups and heteroaryl classes (halo, alkoxy, amino, cyano, sulfonyl/sulfoxyl, etc.). That does not defeat novelty by itself, but it increases obviousness exposure when prior art already teaches the same scaffold-chemotype with similar functional-group tolerance.

Where obviousness arguments likely concentrate

R⁴ tail / amine substitution pattern: because R⁴ is defined as -[alkylene]ᵖ-NR¹⁰R¹¹, it likely corresponds to a known medicinal chemistry region (solubility, binding interactions, or hinge-region mimic). Prior art disclosing the same or near-same tail architecture would undercut the genus.
R¹⁵/R¹⁶/R¹⁷ and m¹: these are typical optimization variables (small alkyl vs t-butyl; hydrogen vs methyl; ring substitution count). Prior art with close analogs usually makes it easier to argue that the remaining “tuning knobs” are routine.
A² aryl/heteroaryl range: the dependent claim 10 enumerates many concrete A² values, which suggests the invention’s contribution is tied to matching a target binding region with a set of tolerated rings. If those same rings were already used in close analogs, the step from prior art to the claimed genus can look incremental.

Is the claim set enforceable against competitors?

Enforcement depends on whether competitors would fall within claim 1’s genus boundaries or can be designed out via:

selecting substituents outside the defined sets,
changing the core scaffold so that X¹ is not a carbonyl in the claimed position,
altering R⁴ from the required -alkylene-NR¹⁰R¹¹ construct,
selecting R¹⁵ values other than ethyl/isopropyl/t-butyl/phenyl,
shifting m¹ outside 0-2,
removing the required stereochemical patterns if those are needed for infringement under specific embodiments (though claim 1 is not stereochemically limited).

The key competitive design-around levers (structural)

From claim language alone, competitors can target several “must-match” elements:

X¹ must be —C(O)
Any redesign that eliminates or relocates this carbonyl at the specified scaffold position avoids claim 1.
R⁵ selection constraints
Claim 1 limits R¹⁵ to four options. If a competitor uses another group (e.g., cyclopropyl, n-propyl, benzyl), it likely avoids at least dependent claims 2.
p = 0 or 1 and R⁴ tail form
R⁴ is defined with p restricted to 0-1 and alkylene as straight chain with defined substitution possibilities. A different linker type, branching, or non-straight alkylene would be a strong escape.
R¹⁰/R¹¹ “hydrogen then R¹¹ must be hydroxy/alkoxy” condition
This is a conditional claim limitation. Competitors can use the option R¹⁰ ≠ H or choose substituents that violate the condition while retaining similar properties.

Where claim 13 affects competitive freedom

Claim 13 is a long explicit list of named chemical embodiments, including many benzamide compounds with stereochemistry and specific ring substitutions. Claim 13 can matter in two ways:

It supports interpretation of the genus by showing the patentee considered a wide set of implementable embodiments within the claim 1 framework.
It provides litigation-ready infringement targets: if a competitor’s product matches any named embodiment, the infringement case is much cleaner than arguing indirect coverage of a distant genus variant.

What does the claim 13 list imply about patent landscape density?

Even without external citation, the sheer size and diversity of claim 13 suggests:

The genus was likely built around a specific pharmacophore and validated across many substituted aromatic and tail variants.
Competitors entering the same target space often generate many close analogs and can easily land within the same Markush boundaries.

This creates a landscape where:

there may be dense follow-on patent coverage around the same scaffold (common in successful series),
and where newer entries must work harder to design around (scaffold shift or linker change) rather than making simple substitution changes.

Key friction points for validity and enforceability

1) Combination therapy claims are broad and likely weak on novelty

Claims 15-16 do not require any specific mechanistic relationship between the compound of claim 1 and the “additional agent.” They just state a pharmaceutical composition with “an additional agent for treatment of cancer,” and enumerate many standard agents. In practice, such claims often face obviousness challenges because the “pairing” is already known or routine.

2) The genus is extremely wide relative to the finite list of exemplified embodiments

A common issue in pharmaceutical Markush claims is whether the disclosure supports the breadth. Claim 1 ranges across many functional groups and ring systems. If the specification does not enable and support the full breadth (including the full range of variable substitutions), that becomes a validity vulnerability in some jurisdictions and proceedings.

3) Claim 1 reads as a “chemotype with many handles”

The presence of many optional substitution variables (A² substitutions, A substitutions, R⁸, R⁴ terminal groups, ring count m¹, and small substituent choices for R¹⁵/R¹⁶/R¹⁷) increases the risk that prior art will locate a subset of these variables in a predictable optimization path.

Claim construction and infringement posture: how courts will likely read it

A competitor’s infringement analysis would be executed in two passes:

Formula element mapping to claim 1
Map X¹, A², A, R⁸, R⁴ (including p, alkylene, and NR¹⁰R¹¹), R¹⁵, R¹⁶, R¹⁷, and m¹.
Dependent claim mapping only after claim 1 hit
If a competitor avoids claim 1 by changing any required element, dependent claims 2-12 do not apply. If claim 1 hits, dependent claims help narrow which specific infringement theories are strongest.

The large explicit claim 13 list makes “hit any embodiment” a practical litigation objective for the patentee, while the broad genus makes “prove it falls within claim 1” a fallback position.

Key Takeaways

US 7,576,221 claim 1 is a very broad Markush genus with multiple independent substituent variables, making coverage potentially wide across a class of scaffold variants. The genus is enforced structurally by X¹ = —C(O)— and R⁴’s -[alkylene]ᵖ₋NR¹⁰R¹¹ tail architecture, plus narrow constraints like R¹⁵ ∈ {ethyl, isopropyl, t-butyl, phenyl}.
Dependent claims 2-12 and 18 provide enforceable anchors by narrowing R¹⁵, R¹⁶/R¹⁷, and enumerating specific A/A²/R⁴ options.
Claim 13 is a litigation-ready list of specific embodiments with stereochemistry and detailed substitution patterns; it supports straightforward infringement mapping if a competitor’s compound matches any listed example.
Combination therapy claims 15-16 are structurally broad and likely validity-fragile because they add standard cancer agents without requiring any specific mechanistic or synergy limitation tied to the claimed compounds.
Competitive design-around must target core scaffold and required tail/linker definitions rather than substituting minor groups, because claim 1’s breadth and the explicit claim 13 coverage reduce the effectiveness of incremental modifications.

FAQs

1) What is the most important claim for infringement risk?
Claim 1. It defines the compound genus with the majority of structural requirements; dependent claims apply only if claim 1 is satisfied.

2) Which claim elements look like “must-match” structural features rather than optional preferences?
X¹ = —C(O)—, R⁴’s -[alkylene]ᵖ-NR¹⁰R¹¹ format with p = 0 to 1, and the limited selection for R¹⁵ (ethyl, isopropyl, t-butyl, phenyl).

3) Do the dependent claims change the scaffold or just constrain substituent choices?
They constrain substituent choices (R¹⁵, R¹⁶/R¹⁷, specific sets for A, A², and enumerated R⁴ options) rather than changing the foundational formula frame.

4) Are the combination therapy claims meaningful protection?
They add broad composition coverage with standard cancer therapies listed in claim 16, but they are not tied to specific synergistic interaction limitations in the claim text.

5) How does claim 13 affect competitor strategy?
It increases the probability that a marketed or developed compound will match at least one enumerated embodiment, so competitors should screen against the named list in claim 13 in addition to evaluating claim 1 genus coverage.

References

[1] United States Patent 7,576,221 (claims as provided in prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	⤷ Start Trial	2025-06-20
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	February 19, 2002	⤷ Start Trial	2025-06-20
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	⤷ Start Trial	2025-06-20
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	⤷ Start Trial	2025-06-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 7,576,221

Summary for Patent: 7,576,221